GSK hits back in high-stakes RSV vaccine game, posting phase 3 data that suggest it has edge on Pfizer

GSK was hiding a strong hand in the high-stakes respiratory syncytial virus (RSV) vaccine game. Having kept its phase 3 results under wraps, the Big Pharma has now released data from the trial—and revealed itself to be a genuine challenger for a market targeted by Pfizer, Johnson & Johnson and Moderna.